APC is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains APC status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ARID1A is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ATM is an inclusion eligibility criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain ATM status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

ATR is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BARD1 is an inclusion eligibility criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain BARD1 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

BRCA1 is an inclusion eligibility criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA1 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

BRCA2 is an inclusion eligibility criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA2 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

BRIP1 is an inclusion eligibility criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRIP1 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

BTRC is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BTRC status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CDK12 is an inclusion eligibility criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain CDK12 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

CHEK1 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK1 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CHEK2 is an inclusion eligibility criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain CHEK2 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

CTNNB1 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CTNNB1 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

DDX3X is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains DDX3X status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

DVL1 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains DVL1 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ERBB2 is an inclusion eligibility criterion in 11 clinical trials for esophageal adenocarcinoma, of which 11 are open and 0 are closed. Of the trials that contain ERBB2 status and esophageal adenocarcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 7 are phase 2 (7 open) [3].

FANCA is an inclusion eligibility criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain FANCA status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

FANCB is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCB status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCC is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCC status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCD2 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCD2 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCE is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCE status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCF is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCF status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCG is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCG status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCI is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCI status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCL is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCL status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCM is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCM status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FZD1 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD1 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD10 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD10 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD2 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD2 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD3 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD3 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD4 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD4 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD5 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD5 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD6 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD6 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD7 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD7 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD8 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD8 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD9 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD9 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

GEN1 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains GEN1 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KMT2D is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains KMT2D status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

LRP5 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains LRP5 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

LRP6 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains LRP6 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MCPH1 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MCPH1 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MRE11A is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MRE11A status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MYC is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NBN is an inclusion eligibility criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain NBN status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

PALB2 is an inclusion eligibility criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain PALB2 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

PTEN is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RAD50 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RAD51 is an inclusion eligibility criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD51 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

RAD51B is an inclusion eligibility criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD51B status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

RAD51C is an inclusion eligibility criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD51C status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

RAD51D is an inclusion eligibility criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD51D status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

RAD54L is an inclusion eligibility criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD54L status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

SLX4 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains SLX4 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

SMARCA4 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

TP53 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

WNT1 is an inclusion eligibility criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains WNT1 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].